Published in AIDS Weekly, July 1st, 2002
"The most frequent side-effects due to nevirapine (Viramune), the first non-nucleoside HIV reverse transcriptase inhibitor introduced for clinical use, are cutaneous hypersensitivity reactions," explained Djamel Messaad and colleagues at Arnaud de Villeneuve Hospital, Montpellier University Hospital and Gui de Chauliac Hospital in Montpellier.
Tolerance can be safely, rapidly, and durably induced in patients with limited treatment options who experience such reactions, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.